Updates in CLL Treatment Strategies with Noncovalent BTKis

Author(s):

Catherine C. Coombs, MDBita Fakhri, MD, MPH

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features

EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL

EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP: 9.Expert Insights for Long-Term Treatment Planning in CLL

EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy

EP: 11.Navigating 2L Treatment Options in CLL

EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

EP: 13.Management Strategies for BTKi-Related CVAEs in CLL

Now Viewing

EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis

EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following:

Please comment on the recent FDA approval of pirtobrutinib in patients with CLL who have received at least 2 prior lines of therapy, and briefly highlight key data from BRUIN that led to this approval.